In vivo oxidised cholesterol in atherosclerosis

published in
Atherosclerosis
1993

document version
Publisher's PDF, also known as Version of record

Link to publication in VU Research Portal

citation for published version (APA)

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:
vuresearchportal.ub@vu.nl

Download date: 15. Jun. 2022
In vivo oxidised cholesterol in atherosclerosis

Anton F.H. Stalenhoef, Henne A. Kleinveld, Truus G. Kosmeijer-Schuil, Pierre N.M. Demacker and Martijn B. Katan

Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen and Department of Human Nutrition, Wageningen Agricultural University, Wageningen (The Netherlands)

Key words: Oxidized cholesterol; Modified LDL; Atherosclerosis

Dear Editors,

Evidence has been increasing the last several years that oxidative modification of LDL may play an important role in the pathogenesis of atherosclerosis [1,2]. Further support for the oxidative modification hypothesis is provided by the recent report of Salonen et al. [3] who found that the titre of autoantibodies to malondialdehyde-modified LDL was an independent predictor of the progression of carotid atherosclerosis. Although there is little doubt about the specificity of these antibodies to artificially oxidised LDL [4], direct evidence that LDL oxidation actually takes place in vivo is scarce; most research on oxidation of LDL involves oxidisability in vitro. We have measured circulating cholesterol oxidation products in WHHL rabbits. Six-month-old rabbits (mean \( \pm \) S.D.) serum cholesterol 18.3 \( \pm \) 2.3 mmol/l, mean serum triglycerides 3.2 \( \pm \) 0.9 mmol/l) were fed with either cholesterol-free control chow or chow mixed with the antioxidant probucol in a low dose (10 mg/kg per day). High doses of probucol are known to retard atherogenesis in these animals [5]. One control animal died during the study period. After 6 months of treatment blood was drawn into vacutainer tubes containing EDTA plus 10 mg of reduced glutathione, plasma was prepared immediately and 0.1 mg of the antioxidant butylated hydroxytoluene added per ml. This treatment effectively prevents oxidation in vitro: in plasma of 5 normal volunteers we found total oxysterol levels of 1.36 \( \mu \)mol/l at time 0 and 1.32 \( \mu \)mol/l after 6 month of storage at \(-80^\circ\)C. Cholesterol oxidation products were determined by a modification of our previously described method [6].

The mean concentration of serum cholesterol was unaffected in the control animals (18.6 \( \pm \) 1.3 (http://www.elsevier.com/locate/atherosclerosis)
TABLE 1
PLASMA LEVELS OF OXysterols (µmol/l) IN 3 CONTROL AND 4 PROBUCOL-TREATED WHHL RABBITS (MEAN (S.D.))

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Probucol</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total oxysterols</td>
<td>9.15 (1.33)</td>
<td>4.64 (0.58)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>7α-Hydroxycholesterol</td>
<td>5.04 (0.33)</td>
<td>2.17 (0.64)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>5,6α-Epoxysterol</td>
<td>0.78 (0.44)</td>
<td>0.39 (0.21)</td>
<td>NS</td>
</tr>
<tr>
<td>7β-Hydroxycholesterol</td>
<td>0.69 (0.23)</td>
<td>0.54 (0.09)</td>
<td>NS</td>
</tr>
<tr>
<td>5α-Cholestane-triol</td>
<td>0.88 (0.10)</td>
<td>0.55 (0.09)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>7-Ketosterol</td>
<td>1.41 (0.39)</td>
<td>0.84 (0.11)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>25-Hydroxycholesterol</td>
<td>0.35 (0.13)</td>
<td>0.15 (0.02)</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

vs. 19.0 ± 1.9 mmol/l), whereas there was a slight decrease in the probucol treated animals (17.7 ± 2.4 vs. 14.2 ± 1.8 mmol/l). Ingestion of a low dose of probucol caused a 50% difference in the levels of circulating cholesterol oxidation products (oxysterols) (Table 1).

This study provides direct evidence that oxidised lipoproteins occur in vivo in the circulation and that administration of low doses of probucol can prevent oxidation to a large extent, explaining its anti-atherogenic effect in WHHL rabbits.

References